PRINCETON, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the publication of a new economic study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five European countries.”1 The purpose of this evaluation was to assess the budget-impact of switching patient treatment from fibrin glue to DuraSeal Polyethylene Glycol (PEG) hydrogel in five major Eur ...

Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 41 cents for the third quarter of 2024, a 46.1% plunge year over year. The metric, however, surpassed the Zacks Consensus Estimate by 5.1%.The adjustment excludes the impact of certain non-recurring charges like structural optimization charges, the Boston recall/Braintree transition and EU Medical Device Regulation charges among others.GAAP loss per share in the third quarter was 14 cents against GAAP EPS of 24 c ...

INTEGRA _ Q3 2024 Earnings Presentation November 4, 2024 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," " ...

Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.13%. A quarter ago, it was expected that this medical device maker would post earnings of $0.62 per share when it actually produced earnings of $0.63, delivering a surprise of 1.61%.Over the last four quarte ...

Core Viewpoint - Integra LifeSciences Holdings Corporation has appointed Mojdeh Poul as the new president and CEO, effective January 6, 2025, succeeding Jan De Witte, who will remain in his role until that date [1][2]. Group 1: Leadership Transition - Mojdeh Poul brings extensive experience in global healthcare, having previously served as executive vice president and group president for 3M's $8.5 billion Global Healthcare Business, overseeing R&D, manufacturing, and commercial operations [2]. - Poul has a proven track record in business strategy, transformation, and leadership development, which is expected to be critical for Integra's strategic and operational plans [2][3]. - Jan De Witte is recognized for his contributions to Integra, particularly in growing the international business and integrating digital technology into the product pipeline [5]. Group 2: Company Background - Integra LifeSciences is focused on restoring patients' lives through innovative treatment pathways and aims to set new standards in surgical, neurologic, and regenerative care [6]. - The company has a comprehensive portfolio of high-quality leadership brands and has been a pioneer in medical innovations for 35 years [6].

PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to partic ...

Integra LifeSciences Holdings Corporation (IART) is well-poised to grow in the coming quarter, driven by healthy sales growth within its Tissue Technologies business despite product recall and manufacturing pause in Boston. The strong performance of the company's Codman Specialty Surgical (CSS) arm is encouraging. Meanwhile, headwinds such as a dull macro environment and currency fluctuations pose concerns for Integra's operations. In the past year, this Zacks Rank #3 (Hold) stock has lost 55.1% against the ...

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer, will present at the Wells Fargo Healthcare conference on September 4, 2024 at 1:30pm ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciences At Integra Li ...

ESG Report Highlights - Integra LifeSciences issued its latest ESG report, highlighting the company's 2023 ESG performance and ongoing efforts against the ESG strategy and roadmap established three years ago [1] - The company's president and CEO emphasized the importance of innovating treatment pathways to advance patient outcomes and set new standards of care [2] - Integra's ESG report includes highlights in key areas: Environmental, Social, and Governance [2] Environmental Initiatives - Recalculated Scope 1, 2, and 3 emissions and partnered with an external consultant to conduct energy assessments at highest energy usage locations to identify energy reduction opportunities and improve greenhouse gas footprint [2] Social Initiatives - Bolstered diversity and inclusion efforts by adding a new employee resource group [2] - Focused on early-in-career talent by providing support and hands-on experience to diverse college students and graduates [2] Governance Initiatives - Revised Code of Conduct and continued to strengthen anti-bribery and corruption program through ongoing training curriculums and programs [2] Alignment with External Guidelines - Integra prepared its ESG report in alignment with external guidelines and measurement frameworks, including the Global Reporting Index and the Sustainability Accounting Standards Board Index [2] Company Overview - Integra LifeSciences is driven by its purpose of restoring patients' lives and innovates treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care [4] - The company offers a comprehensive portfolio of high quality, leadership brands [4]

Revenue Discussion - Tissue Technologies revenues totaled $116.4 million in the second quarter, up 5.6% year over year on a reported basis and 5.7% on an organic basis, driven by high-double-digit growth in DuraSorb, mid-double-digit growth in Gentrix, and low double-digit growth in MicroMatrix, Cytal, and amniotics [2] - Total revenues in the reported quarter rose 9.7% year over year to $418.2 million, surpassing the Zacks Consensus Estimate by 1.4%, with organic growth of 2.3% year over year [19] Profitability - Adjusted operating profit was $0.7 million, down 95.6% year over year, with adjusted operating margin contracting 391 basis points year over year to 0.2% [3] - Gross profit totaled $225.9 million, up 9.1% year over year, but gross margin contracted 27 basis points to 54% [11] Guidance - For 2024, the company projects revenues in the range of $1.61 billion to $1.63 billion, down from previous guidance of $1.67 billion to $1.69 billion, indicating reported growth of 4.4% to 5.7% and organic growth of -1% to 0.3% [13] - For the third quarter of 2024, reported revenues are expected to be in the range of $372 million to $382 million, suggesting reported growth of -2.6% to 0.0% and organic growth of -9.4% to -6.7% [23] Financial Position - The company exited the second quarter of 2024 with cash and cash equivalents of $215.2 million, down from $591.9 million at the end of the first quarter [12] - Cumulative net cash flow from operating activities at the end of the second quarter of 2024 was $56.2 million compared to $54.4 million at the first-quarter end [30] Segmental Details - Revenues in the Codman Specialty Surgical (CSS) segment rose 11.3% year over year to $301.8 million, with organic growth of 0.9% attributed to high-single-digit growth in Dural Access and Repair, low-single-digit growth in advanced energy, and low-double-digit ENT growth [28] Expenses - Selling, general and administrative expenses increased 18.5% to $195.5 million, while research and development expenses rose 11.9% to $29.8 million [29] Earnings - Adjusted earnings per share (EPS) were 63 cents in the second quarter of 2024, down 11.3% year over year, but surpassed the Zacks Consensus Estimate by 1.6% [9] - The company projects adjusted EPS guidance for 2024 between 36 to 44 cents, down from the previously guided range of 3.01 to 3.11 [14][31]